BioXcel Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview

BioXcel Therapeutics

02/08/2024 15:52

* BioXcel Therapeutics Inc  BTAI.OQ   BTAI.O  is expected
to show
a rise in quarterly revenue when it reports  results on August 6
for the period ending June 30 2024
    * The New Haven Connecticut-based  company is expected to
report a
66.1% increase in revenue to $759.2 thousand from $457 thousand
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for BioXcel Therapeutics Inc
is
for a loss of 71 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for BioXcel
Therapeutics Inc is $7.00​, above​ its last closing price
of $1.03. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.64       -0.70      -0.87     Missed  -24.6
 Jan. 1 2024   -0.94       -0.91      -0.76     Beat    16.5
 Sep. 30 2023  -1.34       -1.30      -1.72     Missed  -31.9​
 Jun. 30 2023  -1.80       -1.75      -1.83     Missed  -4.5
 ​​Mar.        -1.81       -1.62      -1.84     Missed  -13.7
 31 2023                                                
 Dec. 31 2022  -1.49       -1.45      -1.95     Missed  -34.8​
 Sep. 30 2022  -1.33       -1.35      -1.49     Missed  -10.5
 Jan. 1 0001   -1.23       -1.22      -1.35     Missed  -10.7
 This summary was machine generated August 2 at 14:52 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)